RxDoctor Payments Data

Ali Khaki, MD

Medical Oncology · Stanford, CANPI 1407299530

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$547,317in research payments, 2019–2025

Across 51 payments — averaging $10,732 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$381K
  • Pfizer$167K

How this compares

$0 in reported general payments places this provider in the 0th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Medicare billing

Part B allowed, 2024
$171,610
Medicare patients
284
Services billed
1,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide27$339,397
Abiraterone Acetate87$48,665
EliquisApixaban13$7,184
Prednisone80$342
Prochlorperazine Maleate23$200
Ondansetron Hcl30$149
Dexamethasone16$130
Tamsulosin Hcl13$86

Paid to pharmacies, not to this prescriber.

Other medical oncology in Stanford

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →